Immune checkpoint inhibitors (ICIs), such as programmed death-1(PD-1)/programmed death ligand-1 (PD-L1) antibodies, have been recognized as standard care for patients with advanced non-small cell carcinoma (NSCLC). The gene discussed is CD274; the disease is non-small cell lung carcinoma.